WHO adds first maternal RSV vaccine to prequalification list
Pfizer’s Abrysvo is designed to prevent RSV-associated disease in infants
Read More
Tag: Abrysvo
Pfizer’s RSV vaccine receives EC approval to protect infants and older adults
The decision follows a recent recommendation from the European Medicines Agency’s human medicines committee
Read More
Pfizer’s maternal RSV vaccine receives FDA approval
The decision allows Abrysvo to be given to those who are 32 to 36 weeks into their pregnancy
Read More
- Acoramidis approved for heart condition treatment
- Genomics study launches to optimise childhood cancer care in Ireland
- UCL researchers launch congenital muscular dystrophy research programme
- Novavax shares positive real-world results for JN.1-adapted COVID-19 vaccine
- FDA approves Click’s digital therapeutic for episodic migraine
